BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sun J, Cheng H, Hassan MRA, Chan HK, Piedagnel JM. What China can learn from Malaysia to achieve the goal of "eliminate hepatitis C as a public health threat" by 2030 - a narrative review. Lancet Reg Health West Pac 2021;16:100261. [PMID: 34590064 DOI: 10.1016/j.lanwpc.2021.100261] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Tang W, Zhang Y, Li J, Xie Y, Wu D, Ong J, Marley G, Kamarulzaman A, Lu H, Zou F, Smith J, Tucker J, Geng-feng F. Pay-it-forward to increase testing for hepatitis B and C: a community-led randomized controlled trial in China.. [DOI: 10.21203/rs.3.rs-2271626/v1] [Reference Citation Analysis]
2 Yan M, Wu B. Hepatitis B and C mortality from 1990 to 2019 in China: a Bayesian age-period-cohort analysis. Ann Transl Med 2022;10:1384. [PMID: 36660613 DOI: 10.21037/atm-22-5676] [Reference Citation Analysis]
3 Zhao Z, Chu M, Guo Y, Yang S, Abudurusuli G, Frutos R, Chen T. Feasibility of Hepatitis C Elimination in China: From Epidemiology, Natural History, and Intervention Perspectives. Front Microbiol 2022;13:884598. [PMID: 35722351 DOI: 10.3389/fmicb.2022.884598] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Adee M, Zhong H, Reipold EI, Zhuo Y, Shilton S, Chhatwal J. Cost-Effectiveness of a Core Antigen–Based Rapid Diagnostic Test for Hepatitis C. Value in Health 2022. [DOI: 10.1016/j.jval.2022.01.004] [Reference Citation Analysis]
5 Draper B, Yee WL, Pedrana A, Kyi KP, Qureshi H, Htay H, Naing W, Thompson AJ, Hellard M, Howell J. Reducing liver disease-related deaths in the Asia-Pacific: the important role of decentralised and non-specialist led hepatitis C treatment for cirrhotic patients. Lancet Reg Health West Pac 2022;20:100359. [PMID: 35024676 DOI: 10.1016/j.lanwpc.2021.100359] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Mermelstein S, Stevens H. TRIPS to Where? A Narrative Review of the Empirical Literature on Intellectual Property Licensing Models to Promote Global Diffusion of Essential Medicines. Pharmaceutics 2021;14:48. [PMID: 35056944 DOI: 10.3390/pharmaceutics14010048] [Reference Citation Analysis]